منابع مشابه
Treatments for hepatitis B.
New optimism surrounds treatments for chronic hepatitis B (CHB). Interferon- alpha , lamivudine, and adefovir dipivoxil are currently approved by the United States Food and Drug Administration for the treatment of CHB. All 3 treatments possess unique characteristics with respect to their side effect profiles, potencies, and treatment niches within the spectrum of CHB. New agents, which are in v...
متن کاملEconomic evaluation of treatments for chronic hepatitis B.
The aim of this study was to conduct a cost-utility study of adefovir, entecavir, interferon alpha, pegylated interferon alpha, lamivudine and tenofovir for chronic hepatitis B in the context of Brazilian Public Health Care System. A systematic review was carried out for efficacy and safety. Another review was performed to collect utility data and transition probabilities between health states....
متن کاملA Multistage Group Education for Hepatitis B
Abstract Introduction. Hepatitis B is the most common cause of end stage liver disease in Iran. As a high-cost disease with a relatively high incidence, and the relative lack of community knowledge, it warrants initiation of a public health intervention in Iran. Methods. This was a Before-After educational intervention that analyzed the data obtained from questionnaires filled out by 80 pat...
متن کاملEconomic evaluation of chronic hepatitis B treatments in Taiwan.
BACKGROUND AND AIMS Chronic hepatitis B (CHB) and its sequelae are major health problems in Taiwan. The purpose of the present study was the economic evaluation of short-duration treatments of CHB and longer duration antiviral treatment for up to 5 years. METHODS Ten-health state CHB disease progression Markov models were used for hepatitis B e antigen (HBeAg)-positive and HBeAg-negative CHB ...
متن کاملPreventing hepatitis B reactivation due to immunosuppressive drug treatments.
Reactivation of the hepatitis B virus (HBV) can cause severe liver injury resulting in jaundice, liver failure, and death.1 This outcome continues to occur in patients receiving immunosuppressive drug therapy (ISDT) despite the ability to identify persons at risk with readily available and inexpensive blood tests for hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen (...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Infectious Diseases
سال: 2004
ISSN: 1058-4838,1537-6591
DOI: 10.1086/425010